Effects of Oral Dydrogesterone and Oral Medroxyprogesterone Acetate in the Treatment of Abnormal Uterine Bleeding-Ovulatory Dysfunction in ReproductiveAged Women from 18 to 39 years old: A Five-Year Chart Review / [author]: Palabrica, Nicolette Vanesa L. [co-author]: Reyes, Lylah D.
Effects of Oral Dydrogesterone and Oral Medroxyprogesterone Acetate in the Treatment of Abnormal Uterine Bleeding-Ovulatory Dysfunction in ReproductiveAged Women from 18 to 39 years old: A Five-Year Chart Review / [author]: Palabrica, Nicolette Vanesa L. [co-author]: Reyes, Lylah D.
- Fairview, Quezon City: Department of OBgyne, FEU-NRMF, 2023
- ( in folder) with flash drive (soft copy)
Includes bibliographical references.
ABSTRACT:
Background: Anovulatory cycles possess an estrogenic endometrium with absence of progesterone to regulate and organize the endometrium. Hence, one treatment approach for ovulatory dysfunction is the use of progestins to have a scheduled and well-ordered withdrawal bleeding.
Objective: Compare the effects of oral dydrogesterone and oral medroxyprogesterone acetate in the treatment of abnormal uterine bleeding-ovulatory dysfunction among reproductive aged women from 18 to 39 years from 2016 to 2020.
Methods: A five-year retrospective cohort which reviewed charts of women with abnormal uterine bleeding-ovulatory dysfunction who were either given oral dydrogesterone or medroxyprogesterone acetate. Data extracted were patient’s age, gravidity, parity, progesterone agent used, menstrual cycle regularity, frequency of menses, duration of menses, menstrual blood loss score and its adverse effects. Purposive Sampling done. Chi-square and t-test were used to compare the effects of the two progestins.
Result: Eligible for review were 310 charts of women who received oral progestin with 155 cases for each arm. After the 6-month treatment, Dydrogesterone and Medroxyprogesterone acetate both resulted to regular, as well as normal menstrual cycle frequency, duration of menses, and menstrual blood loss (p < 0.05). Their effect on mean frequency, cycle variation, duration, and blood loss volume were comparable.Reported adverse effects were also similar, 46.5% (87) for those with Dydrogesterone and 53.4% (100) with Oral Medroxyprogesterone acetate (p 0.31).
Conclusion: Oral Dydrogesterone and Oral Medroxyprogesterone Acetate when used for
treatment of AUB-0 have comparable effects on the menstrual parameters and reported
adverse effects.
Keywords: Abnormal Uterine Bleeding, AUB-O, Ovulatory Dysfunction, Oral
Medroxyprogesterone Acetate, Oral Dyrogesterone
Department of Obstetrics & Gynecology Research - Department of Obstetrics & Gynecology
OB 2023 0006
Includes bibliographical references.
ABSTRACT:
Background: Anovulatory cycles possess an estrogenic endometrium with absence of progesterone to regulate and organize the endometrium. Hence, one treatment approach for ovulatory dysfunction is the use of progestins to have a scheduled and well-ordered withdrawal bleeding.
Objective: Compare the effects of oral dydrogesterone and oral medroxyprogesterone acetate in the treatment of abnormal uterine bleeding-ovulatory dysfunction among reproductive aged women from 18 to 39 years from 2016 to 2020.
Methods: A five-year retrospective cohort which reviewed charts of women with abnormal uterine bleeding-ovulatory dysfunction who were either given oral dydrogesterone or medroxyprogesterone acetate. Data extracted were patient’s age, gravidity, parity, progesterone agent used, menstrual cycle regularity, frequency of menses, duration of menses, menstrual blood loss score and its adverse effects. Purposive Sampling done. Chi-square and t-test were used to compare the effects of the two progestins.
Result: Eligible for review were 310 charts of women who received oral progestin with 155 cases for each arm. After the 6-month treatment, Dydrogesterone and Medroxyprogesterone acetate both resulted to regular, as well as normal menstrual cycle frequency, duration of menses, and menstrual blood loss (p < 0.05). Their effect on mean frequency, cycle variation, duration, and blood loss volume were comparable.Reported adverse effects were also similar, 46.5% (87) for those with Dydrogesterone and 53.4% (100) with Oral Medroxyprogesterone acetate (p 0.31).
Conclusion: Oral Dydrogesterone and Oral Medroxyprogesterone Acetate when used for
treatment of AUB-0 have comparable effects on the menstrual parameters and reported
adverse effects.
Keywords: Abnormal Uterine Bleeding, AUB-O, Ovulatory Dysfunction, Oral
Medroxyprogesterone Acetate, Oral Dyrogesterone
Department of Obstetrics & Gynecology Research - Department of Obstetrics & Gynecology
OB 2023 0006
